CEO Tried AI in Drug Testing–Here's Why It Failed

In today’s episode, Dinkar Sindhu, CEO of Axis Clinicals, dives into the world of clinical research and the cautious integration of AI in drug development. From testing groundbreaking GLP-1 drugs like Ozempic to navigating the complexities of FDA approvals, Dinkar reveals the meticulous process behind ensuring that new drugs are safe and effective. “AI can help, but it must be traceable and reproducible,” he explains, sharing lessons from a pilot program where inconsistent AI outputs raised red flags. Join us for an insightful look at how clinical trials shape the future of medicine, the challenges of AI in ensuring data integrity, and why human oversight remains vital.